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Abstract Three new cell lines of human glioblastuma have been 
established. These cells co-expressed hepatocyte growth factor 
(HGF) and its receptor, c-Met, genes in vitro. Reverse-transcrip- 
tase/polymerase-chain reaction study revealed that the cells also 
expressed gene for HGF activator, a recently cloned serine pro- 
teinase, suggesting that HGF might have a role in glioma cells 
in vitro as an autocrine factor. The activator mRNA was also 
detected in other well-established glioma cell lines, glioma tissues 
and normal brain. The concomitant expression of HGF, HGF 
activator and c-met was also detected in one glioblastoma case 
in vivo out of live tested. 
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activator (u-PA) was also reported to be a candidate for the 
converting proteinase [12,13]. 
Gliomas are the most common brain tumors. Glioblastoma 
multiforme and anaplastic astrocytoma are high-grade gliomas 
of astrocytic origin and the prognosis for patients with glioblas- 
toma is very poor. Recently a few reports described the expres- 
sion of HGF and c-Met receptor in the normal brain tissue 
[14--16]. However, to date, little is known about the expression, 
functions and roles of these proteins in gliomas. We report here 
the expression ot only of HGF and c-met, but also HGF 
activator mRNAs in cell lines and tissues of gliomas, particu- 
larly glioblastoma multiforme. 
2. Materials and methods 
I. Introduction 
Cellular proliferation and migration participate in one of the 
important aspects of malignant phenotypes of the tumors, par- 
ticularly of brain tumors which rarely metastasize but can kill 
the host by their proliferative and migratory activity in the 
brain that is located in a rigidly confined space, the skull. These 
processes are often mediated by polypeptide growth factors 
acting in either a paracrine or autocrine fashion. Hepatocyte 
growth factor (HGF) is a pleiotropic factor initially identified 
as a polypeptide growth factor for hepatocytes [1,2], and is 
indistinguishable from scatter factor (SF), a motility factor 
[3-6]. HGF functions as a mitogen for a variety of cell types, 
as a morphogen and as a motogen for some epithelial cells [6]. 
Although the roles of HGF in tumors have yet been clarified, 
the identification of its receptor as the c-met proto-oncogene 
product, which was originally described as an activated onco- 
gene in a human osteosarcoma cell line [7], has accelerated 
efforts to determine the roles of HGF in tumors [6]. To generate 
the biological activity of HGF, the proteolytic onversion of the 
single-chain precursor form to the two-chain heterodimer ac- 
tive form is essential [8]. The conversion occurs after secretion 
and takes place in the extracellular environment [8,9]. This 
converting activity was first purified from fetal bovine serum 
[10] and designated as HGF activator, a novel serine proteinase. 
Recently, the HGF activator was also purified from human 
serum and its cDNA was cloned [11]. This HGF activator 
mRNA has been reported to be detected only in the liver with 
Northern blot analysis [11], but the expression of this gene in 
tumors has yet been examined. Urokinase-type plasminogen 
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2.1. Cell culture 
MGM-1 was derived from a primary tumor of left temporal lobe with 
histological diagnosis of glioblastoma multiforme, removed from a 
64-year-old Japanese male in August 1992. The patient had not received 
other therapies before surgery. MGM-2 was derived from a primary 
tumor of left fronto-parietal lobe with histological diagnosis of glioblas- 
toma multiforme, removed from a 37-year-old Japanese male in De- 
cember 1993. The patient had not received other therapies before sur- 
gery. MGM-3 was derived from a recurrent tumor of right frontal lobe 
with histological diagnosis of glioblastoma multiforme, removed from 
a 73-year-old Japanese female in July 1994. Prior to the surgery, chemo- 
and radiation-therapy were done. For primary culture, fragments ofthe 
surgically resected tumors were rinsed repeatedly with phosphate-buff- 
ered saline, minced finely and digested in 0.2% collagenase (Wako 
Junyaku, Osaka, Japan), 1000 U/ml dispase (Sanko Junyaku, Tokyo, 
Japan) in Dulbecco's modified Eagle's medium (DMEM) at 37°C for 
2 h. Then the dispersed cells were cultured in DMEM containing 10% 
fetal bovine serum (FBS) and antibiotics. The human glioma cell lines, 
U251 and KG-1-C, were obtained from RIKEN cell bank (Tsukuba, 
Japan) and cultured in the same medium. U251 was derived from a 
glioblastoma multiforme [17], and KG-1-C was from a mixed glioma 
and has features of oligodendroglioma [18]. A human pancreas 
adenocarcinoma cell line SUIT-2 [19] was kindly provided by Dr. T. 
Iwamura, First Department of Surgery, Miyazaki Medical College, 
Japan. A human rectal adenocarcinoma cell line, RCM-1, was estab- 
lished in our laboratory [20]. Conditioned media were harvested from 
the confluent cultures after 24 h cultivation. 
2.2. RNA and DNA extraction 
Total RNA was extracted from the tissue samples by Trizol (Gibco 
BRL, Gaithersburg, MD) followed by poly(A) ÷ RNA selection by using 
oligo(dT)-Latex (Takara Shuzo, Shiga, Japan) according to the manu- 
facturer's instructions. Poly(A) + RNA was extracted from the cultured 
cells by using FastTrack mRNA isolation kit (Invitrogen, San Diego, 
CA). The chromosomal DNA was extracted by using DnaQuick DNA 
extraction kit (Dainippon Seiyaku, Osaka, Japan). Human whole brain 
poly(A) ÷ RNA was purchased from Clontech (Palo Alto, CA). 
2.3. Reverse-transcriptase/polymerase-chain r actio (RT-PCR) 
For cDNA synthesis, 0.1 /lg of poly(A) ÷ RNA was reverse-tran- 
scribed with oligo(dT)~ 5 and SuperScript reverse transcriptase (Gibco 
BRL) according to the manufacturer's instruction. For PCR, the 
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cDNA samples were brought o a final concentration f 50 mM KCI, 
10 mM Tris (pH 8.3), 1.5 rnM MgCI2, 0.001% gelatin, 200 pM dNTPs 
and 7 mM anti-Taq polymerase rnonoclonal antibody (Clontech). In 
addition, each sample contained 0.1 pmol of both reverse and forward 
primers and 2.5 U of Taq polymerase (Takara). PCR was carried out 
in a programmable h ating block (Perkin Elmer Cetus, Norwalk, CT) 
using 5 cycles consisting of denaturation at94°C for 1 rain, annealing 
at 55°C (for HGF activator) or 58°C (for HGF and c-met) for 2 min 
and extension at 72°C for 2 min, followed by 30 cycles consisting of 
94°C for 30 s, 55°C or 58°C for 1 min and 72°C for 2 min. Products 
were analyzed by 2.5% agarose gel electrophoresis. The products were 
also subcloned into TA cloning vector, pCR II (Invitrogen, San Diego, 
CA) and the nucleotide sequences were determined by the dideoxy 
chain-termination method. 
2.4. Primers for PCR 
The sequence of the forward primer for HGF activator, HGFA-s3 
and HGFA-s4, are 5'-AGGACACAAGTGCCAGATTG-3' and 5'- 
CGACGGACGTGACGCAGACC-3', respectively, and correspond to 
bases 1593-1612 and 1409-1428, respectively, of the HGF activator 
sequence [11]. The sequences of reverse primers for HGF activator, 
HGFA-as2 and HGFA-as4, are 5'-TCGGACTTGCAGTCGAAGTA- 
3' and 5'-GTTGATCCAGTCCACATAGT-3', respectively, and are 
complementary to bases 1756-1775 and 1907-1926, respectively, of the 
HGF activator sequence [11]. The sequences of the forward primers for 
c-met, MET-sl and MET-s2, are 5'-ATTCATCAGGCTGTGAA- 
GCG-3' and 5'-ACAGTGGCATGTCAACATCGCT-3', respectively, 
and are complementary to bases 1214-1233 and 2413-2434, respec- 
tively, of the c-met sequence [21]. The sequences of the reverse primers 
for c-met, MET-asl and MET-as2, are 5'-CAGAGAGGCATTGACT- 
GCAG-3' and 5'-GCTCGGTAGTCTACAGATTC-3', respectively, 
and are complementary to bases 1575-1594 and 3049-3068 [21]. The 
sequences of the forward primers for HGF, HGF-s2 and HGF-s3, are 
5'-GGGAAATGAGAAATGCAGCCAG-3' and 5'-TCACGAGCAT- 
GACATGACTCC-3', respectively, and are complementary to bases 
1911-1932 and 1002 1022, respectively of the HGF sequence [22]. The 
sequences of the reverse primers for HGF, HGF-as2 and HGF-as3, are 
5'-AGTTGTATTGGTGGGTGCTTC-3" and 5'-AGCTTACTTGCA- 
TCTGGTTCC-3', respectively, and are complementary to bases 2205 
2225 and 1284-1304. respectively, of the HGF sequence [22]. 
2.5. Enzyme immunoassay 
Amount of HGF protein in the culture conditioned media were 
measured by the sandwich enzyme immunoassay [23] (EIA) (Otsuka 
Seiyaku, Tokyo, Japan). 50 ,ul of unconcentrated conditioned medium 
was used for each assay. FBS (10%) containing medium was used as 
a control. The assays were performed in duplicate and were presented 
as mean values. The amount of u-PA antigen in the conditioned media 
was also measured by the sandwich EIA kit (Biopool, Ume~t, Sweden). 
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Fig. 1. RT-PCR for HGF mRNA. Poly(A) + RNA preparations derived 
from cultured cells (lanes 1 5) and tissues (lanes 6-11) were used for 
the reaction. Products (10/.tl of each) were analyzed in 2.5% agarose 
gel electrophoresis. The 315 bp (a) and 303 bp (b) fragments were 
obtained with different combination of primers (HGF-s2-as2 and -s3- 
as3, respectively). Lane 1 = MGM-1; lane 2 = MGM-2; lane 
3 = MGM-3; lane 4 = KG-1-C; lane 5 -= U251; lane 6 = glioblastoma 
multiforme (GBM)-I; lane 7 = GBM-2; lane 8 = GBM-3; lane 9 = an- 
aplastic astrocytoma (A.Astro.)-l; lane 10 = A.Astro.-2; lane 11 = nor- 
mal brain (whole-brain). 
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Fig. 2. RT-PCR for c-met mRNA. Poly(A) + RNAs derived from cul- 
tured cells (lanes 1-5) and tissues (lanes 6-11) were used. The 381 bp 
(a) and 656 bp (b) fragments were obtained with different combination 
of primers (MET-sl-asl and -s2-as2, respectively). Lane 1 = MGM- 
1; lane 2=MGM-2; lane 3=MGM-3; lane 4=KG-1-C; lane 
5 = U251; lane 6 -- GBM-1; lane 7 = GBM-2; lane 8 = GBM-3; lane 
9 = A.Astro.-l: lane 10 = A.Astro.-2; lane ll = normal brain. 
3. Results 
3.1. Secretion of HGF by glioma cells in vitro 
Antigen levels of HGF in the conditioned media of four 
glioma cell lines were measured by EIA. As shown in Table 1, 
two cell lines (MGM-1 and KG- I -C)  out of four produced 
detectable amounts of HGF into the conditioned media. 
3.2. Expression of HGF and c-met genes in gliomas 
Expression of HGF gene was also confirmed by RT-PCR 
study. Four cell lines (MGM-1, -2, -3 and KG-1-C) out of five 
expressed the HGF mRNA.  Both primer sets (HGF-s2-as2 and 
-s3-as3) yielded products of the expected sizes (Fig. 15. The 
mRNA was detected even in MGM-3 cells in which HGF 
antigen was undetectable in the conditioned medium by EIA 
(Table 1). Next, we analyzed the expression of mRNA for 
c-Met protein, the receptor for HGF. All the cell lines expressed 
c-met gene (Fig. 2), and thus only U251 expressed c-met gene 
without co-expression of HGF gene. When analyzed in the 
surgically resected glioma tissues (three glioblastomas and two 
anaplastic astrocytomas), HGF mRNA was also detected with 
RT-PCR analysis, however, mRNA for c-met was detectable 
only in one case (GBM-3; Fig. 2, lane 8). On the other hand, 
in normal brain (whole-brain poly(A) ÷ RNA), both mRNAs 
were clearly detected (Figs. 1 and 2). 
3.3. Expression of HGF activator gene in gliomas 
Finally, we examined the expression of HGF activator gene 
in the glioma cell lines and tissues, With RT-PCR study, all 
glioma samples, except for one anaplastic astrocytoma tissue, 
expressed the activator mRNA.  Furthermore normal brain tis- 
sue (whole-brain) also expressed this gene. Both primer sets 
(HGFA-s3 as2 and -s3-as4) yielded products of the expected 
Table 1 
Secretion of HGF by cultured glioma cell lines 
Cells (ng/ml) (ng/107 cells/24h) 
MGM-1 0.56 2.77 
MGM-3 <0.3 
KG-1-C 1.81 140.5 
U251 <0.3 
Confluent cells were cultured in DMEM, 10% FBS, for 24 h and 
conditioned media were harvested and analyzed. 
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Fig. 3. RT-PCR for HGF activator mRNA. Poly(A)* RNAs derived 
from cultured cells (lanes 1 5) and tissues (lanes 6-11) were used. The 
183 bp (a) and 334 bp (b) fragments were obtained with different 
combination of primers (HGFA-s3-as2 and -s3 as4, respectively). 
Lane 1 = MGM-1; lane 2 = MGM-2; lane 3 = MGM-3; lane 4 = KG- 
I-C; lane 5 = U251; lane 6 = GBM-I; lane 7 = GBM-2; lane 8 = GBM- 
3; lane 9 = A.Astro.-1; lane 10 = A.Astro.-2; lane 11 = normal brain. 
sizes (183 bp and 334 bp, respectively) (Fig. 3, Table 2). Other 
primers sets, HGFA-s4-as2 and -s4~as4, were also examined 
in cases of KG-1-C and a glioblastoma tissue, and bands of 
expected sizes (367 bp and 518 bp, respectively) were also de- 
tected (Table 2). To confirm that the RT-PCR products are 
derived from mRNA, not from the contaminated genomic 
DNA, the genomic DNA preparation from MGM-1 and U251 
cells were also amplified by using the same primer set (HGFA- 
s3-as2). This primer set generated ~ 280 bp product when the 
genomic DNA was amplified suggesting that between these 
primers there might exist ~ 100 bp intron sequence (Fig. 4A). 
Sunsequent sequencing of the ~ 280 bp product revealed that 
there is an additional sequence between the nucleotide no. 1636 
and 1637 (numbers are according to Miyazawa et al. [11]) (Fig. 
4B). This additional sequence had conserved sequences for 
introns, i.e. GT at the 5'-end and AG at the 3'-end (Fig. 4B). 
Furthermore, PCR of the genomic DNA preparation by using 
primers HGFA-s3 and -as4 generated products larger than 
1000 bp, that could be re-amplified by an internal primer set 
such as HGFA-s3-as2 (Fig. 4A). Therefore it would be appar- 
ent that the 183 bp (HGFA-s3-as2) and 334 bp (HGFA-s3- 
as4) RT-PCR products were derived from mRNA for HGF 
activator, not from contaminated genomic DNA. In addition, 
both of the 183 and 334 bp products were sequenced and found 
Table 2 
Summary of the RT-PCR experiments 
HGF c-met HGF 
-s2-as2/-s3 -sl-asl/-s2 activator 
as3 as2 -s3~s2/-s3- 
as4/-s4-as2 
Cell lines (histology of the original tumor) 
MGM-1 (GBM) +/+ +/+ +/+/n.t. 
MGM-2 (GBM) +/+ +/+ +/+/n.t. 
MGM-3 (GBM) +/+ +/+ +/+/n.t. 
KG-1-C (mixed glioma) +/+ +/+ +/+/+ 
U251 (GBM) - /+ +/+ +/+/n.t. 
SUIT-2 (Ad) / +/+ - / -  
RCM-1 (Ad) n.t. n.t. - / -  
Tissues 
GBM- 1 +l+ - l -  +l+l+ 
GBM-2 -/+ - l -  +/+/n.t. 
GBM-3 +/+ +/+ +/+/n.t. 
A.Astro.- 1 +/+ - / -  +/+/n.t. 
A.Astro.-2 - /+ - /+ _+/-/n.t. 
Normal brain 
(whole brain) +/+ +/+ +/+/n.t. 
GBM: Glioblastoma multiforme; A.Astro.: Anaplastic astrocytoma; 
Ad: Adenocarcinoma 
+: single band of expected size; +: only a faint band of expected size; 
-: no visible band of expected size; n.t.: not tested 
to be completely identical to the sequence of HGF activator 
cDNA reported previously [11]. Two human adenocarcinoma 
cell lines, SUIT-2 and RCM-1, did not express detectable 
amounts of HGF activator mRNA. 
The results of RT-PCR studies are summerized in Table 2. 
It should be emphasized that concomitant expression of HGF, 
its receptor c-Met, and HGF activator genes was found in four 
glioma cell lines out of five tested and in one glioma tissue out 
of five. 
3.4. Secretion o f  u-PA by the cultured glioma eells 
Secretion of u-PA protein, another candidate for the HGF 
activation [9,10], in the culture conditioned media of glioma cell 
lines was measured by EIA. All cell lines, except for MGM-2, 
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Fig. 4. PCR of the genomic DNA preparation with the primer sets for HGF acitvator (A). Lane 1 shows control RT-PCR product (183 bp) by using 
liver total RNA. Lane 2 and 3 show PCR products by using the genomic DNA derived from MGM-1 and U251, respectively. One ,ug of genomic 
DNA was used as template. The primer sets used are HGFA-s3-as2 (a) and HGFA-s3-as4 (b). Subsequent sequencing of the -280 bp products (lanes 
2a and 3 a) revealed the presence ofa presumed intron sequence between nucleotide no. 1636 and 1637 of HGF activator cDNA sequence [11] (B). 
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Fable 3 
Secretion of u-PA by cultured glioma cell lines 
Cells (ng/ml) (ng]10 vcells/24h) 
MGM-1 91.0 450.1 
MGM-2 n.d. n.d. 
MGM-3 18.3 225.0 
KG-1-C 0.08 6.2 
U251 7.7 30.3 
Confluent cells were cultured in DMEM, 10% FBS, for 24 h and 
conditioned media were harvested and analyzed, n.d. : not detectable. 
secreted etectable amount of u-PA (Table 3). Particularly, 
MGM-1 and -3 cells secrete a large amount. 
4. Discussion 
This study describes the RT-PCR analysis of gene expression 
for HGF activator, HGF and c-met in human gliomas and 
normal brain. Of these, to the best of our knowledge, expres- 
sion of HGF activator has not been examined in the tumor cells 
and the brain tissue so far. In the present communication we 
report for the first time that glioma cells express HGF activator 
gene, and that the normal brain tissue also express this gene. 
HGF is a multifunctional, heparin-binding glycoprotein i i- 
tially identified as a potent mitogen for hepatocytes [1,2]. The 
c-met proto-oncogene product, a membrane-bound tyrosine 
kinase, was demonstrated to represent the high affinity HGF 
receptor suggesting the roles of HGF in tumor progression [6]. 
HGF is thought o be mainly a paracrine factor produced by 
mesenchymal cells [6], however, an autocrine activity was re- 
ported in osteosarcoma cells very recently [24]. Furthermore, 
creation of HGF autocrine loop in carcinoma cells induced 
invasiveness and increased tumorigenicity [25]. Human HGF 
is synthesized as a 728-amino acid precursor followed by re- 
moval of the N-terminal 31 amino acid residues as a signal 
peptide. HGF is then secreted as a single-chain i active form 
[6]. It has been shown that proteolytic conversion of the single- 
chain form to the two-chain heterodimer is essentially required 
for biologic activity [8]. The conversion occurs in the extracellu- 
lar environment after secretion [8,9]. Therefore the converting 
proteinase must be a key player in the regulation of HGF 
activity particularly in cellular microenvironment. HGF activa- 
tor is a recently reported serine proteinase which shows homol- 
ogy to blood coagulation factor XII, and is thought to be 
synthesized by the liver [11]. It cleaves the bond between Arg 494 
and Va1495 in the single-chain HGF to generate the active two- 
chain form [8,11]. Another candidate for the HGF-activation 
is u-PA [12,13]. 
In the present communication, we described that cultured 
glioma cells express both HGF and its receptor c-Met protein 
genes. The co-expression of these genes in the glioma cells 
would lead to a functional interaction of the products in vitro. 
Furthermore, the cells also expressed HGF activator gene and 
secreted u-PA protein. The surgically resected glioma tissues 
also expressed HGF and HGF activator genes. In addition, 
elevated level of u-PA in glioblastomas has also been reported 
recently [24]. The production of HGF activator and u-PA, in 
addition to HGF and c-Met, by glioma cells themselves might 
have a great advantage of creating an autocrine loop of HGF 
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in the glioma cell microenvironment. Interestingly, although all 
glioma cell lines expressed c-met in vitro, only one out of five 
glioma tissues examined in this study expressed notable amount 
of c-met mRNA in vivo (Table 2). Two possibilities can be 
considered to explain this finding. First, the expression of c-met 
is induced in vitro, and thus is an artifact of the tissue culture 
environment. Second, the tissue culture nvironment selects for 
a minor population of cells that express c-met in vivo. In either 
case, the concomitant expression of c-met, HGF and its activa- 
tors may somehow provide an advantage of adapting to the in 
vitro condition by creating the autocrine loop and thus the 
frequent expression of c-met in vitro may be a feature of the 
tissue culture environment. However, we have found at least 
one case of glioblastoma that co-express c-met, HGF and HGF 
activator in vivo suggesting that the creation of the autocrine 
loop can also occur even in vivo in limited cases of glioma. 
To date, little is known about the biological roles of HGF 
in gliomas [6]. Expression of HGF gene has been reported in 
the normal brain tissue, particularly in neurons [16]. Immu- 
nohistochemically, HGF and its receptor c-Met protein were 
reported to be positive in astrocytes and microglia, respectively 
[14,15]. Amplification of c-met gene has recently been described 
in glioblastoma cell line and tissues [27-29], however, expres- 
sion of HGF and c-met mRNAs in glioma has yet been clarified 
so far. DiRenzo et al. [30] described that one out of four glioma 
tissues examined expressed c-met mRNA, and this positive case 
was malignant glioma infiltrating the brain. In fact, we have 
found a chemotactic activity of HGF for U251 cells which 
expressed c-met in vitro (unpublished observation). Therefore, 
it is of interest to know whether the expression of c-met in vivo 
is a prognostic parameter in glioma. 
In conclusion, although the biological functions of HGF 
were yet uncertain in glioma cells, the observations described 
here provide evidence for the hypothesis that HGF is acting as 
an autocrine factor in glioma cells in vitro and in limited cases 
of primary glioma in vivo. Further efforts would be necessary 
to explore the potential relevance of HGF, HGF activator and 
c-met in gliomas, particularly glioblastoma multiforme. Fur- 
thermore, the finding that HGF activator is also expressed in 
the normal brain would accelerate the efforts to determine the 
roles of HGF in the brain. 
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